Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
50 participants
OBSERVATIONAL
2025-07-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Immune Base of Endometriosis
NCT00370123
Endometriosis and Chronic Endometritis
NCT05824507
Endometrial Markers in Autoimmune Diseases
NCT03843034
Diagnostics of Chronic Endometritis in Infertility
NCT05946655
Evaluation of M1 and M2 Macrophages in Endometriotic Tissue of Women Affected by Endometriosis at Different Stages.
NCT03136978
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A 2 ml endometrial biopsy will be collected using the NEXODIS suction cannula on day 20-22 of the cycle, after confirmation of a negative result of B-human chorionic gonadotropin in the blood, and divided into 2 parts: 1 ml will be secured and sent for cytometric examination. At the same time, a peripheral blood sample (10 ml) will be collected in accordance with the SU in-hospital procedure and sent for cytometric examination.
Labeled blood cells and isolated single endometrial cells will be analyzed by flow cytometry using the FACSCanto2 system (BD Biosciences, USA). Blood cells will be stained directly with a panel of antibodies, and endometrial samples will be crushed and filtered before staining to isolate single cells. Then, the stained cells will be washed, erythrocytes will be lysed and centrifuged. It is planned to use a panel of monoclonal antibodies conjugated with fluorochromes, recognising the following markers: CD45, CD56, CD16, CD3, CD64, CD206, CD163, CD80, CD86 and CD138. The study population will be characterised in terms of age, BMI, gynecological data (surgeries, course of the menstrual cycle, nature of bleeding, ultrasound data) and obstetric data (pregnancies, deliveries, miscarriages). Characteristics of the study population, results of cytometric, histopathological, immunohistochemical endometrial and blood cytometric tests and their mutual correlation will be analysed using standard statistical methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Infertility
Women aged 18-45 with idiopathic infertility/recurrent miscarriages
Percentage distribution of immune system cells in peripheral blood
Assessment of the percentage distribution of the immune system cell population in peripheral blood by flow cytometry
Percentage distribution of immune system cells in endometrium
Assessment of the percentage distribution of the immune system cell population in endometrium by flow cytometry
Normal fertility
Women aged 18-45 with a history of normal pregnancy obtained by spontaneous fertilization
Percentage distribution of immune system cells in peripheral blood
Assessment of the percentage distribution of the immune system cell population in peripheral blood by flow cytometry
Percentage distribution of immune system cells in endometrium
Assessment of the percentage distribution of the immune system cell population in endometrium by flow cytometry
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Percentage distribution of immune system cells in peripheral blood
Assessment of the percentage distribution of the immune system cell population in peripheral blood by flow cytometry
Percentage distribution of immune system cells in endometrium
Assessment of the percentage distribution of the immune system cell population in endometrium by flow cytometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* idiopathic infertility
* at least 2 miscarriages
* other benign gynecological conditions subjected to endometrial sampling
Exclusion Criteria
* abdominal/uterine surgery within last 3 months
* viral/bacterial infection within last 3 months
* antibiotic therapy within last 3 months
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jagiellonian University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Iwona Magdalena Gawron
PhD, MD, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kazimierz PityĆski, Prof., PhD
Role: STUDY_CHAIR
Jagiellonian University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1072.6120.301.2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.